Industry News

Biotechnology Industry News

After assuring investors last week…

July 28th, 2025|FierceBiotech|

After assuring investors last week that beleaguered Sarepta Therapeutics would likely fulfill its financial duties in a deal with Arrowhead Pharmaceuticals, the latter has publicly stated that it has surpassed the threshold to earn its

Radiopharmaceuticals-focused…

July 28th, 2025|FierceBiotech|

Radiopharmaceuticals-focused Artbio has drawn in a $132 million series B to push its lead prostate cancer prospect through phase 2 trials and bolster its supply chain.

After months of searching for…

July 28th, 2025|FierceBiotech|

After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans to offer jobs to about half of the biotech’s employees. Once the deal closes, Adaptimmune will

MapLight Therapeutics has raised a…

July 28th, 2025|FierceBiotech|

MapLight Therapeutics has raised a $372.5 million series D round, clearing the biotech to chart a course through phase 2 for its would-be challenger to Bristol Myers Squibb’s schizophrenia treatment Cobenfy.

A phase 3 trial of Celcuity’s…

July 28th, 2025|FierceBiotech|

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for success to tee up a filing for FDA approval in the fourth quarter.

Having recently scored approval…

July 28th, 2025|FierceBiotech|

Having recently scored approval for Nucala in COPD, GSK has now signed a major $12 billion biobucks deal designed to strengthen the pharma’s offering for the respiratory condition.

Bristol Myers Squibb has raided…

July 25th, 2025|FierceBiotech|

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer, persuading Cristian Massacesi, M.D., to leave the Anglo-Swedish drugmaker to take responsibility for all its product development.

The uncertainty around the future…

July 25th, 2025|FierceBiotech|

The uncertainty around the future of Elevidys hasn’t destroyed Roche’s belief in the potential of gene therapies, the Swiss company’s head of pharma has told Fierce Biotech.

A phase 2 trial of Memo…

July 25th, 2025|FierceBiotech|

A phase 2 trial of Memo Therapeutics’ kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication. But the Swiss biotech saw promise in other aspects of

Ikena and Inmagene have selected…

July 24th, 2025|FierceBiotech|

Ikena and Inmagene have selected Kristin Yarema, Ph.D., to lead the company upon the anticipated closing of their merger. Yarema comes from a recent career at Poseida, culminating in CEO before the company was bought

Australian life sciences venture…

July 24th, 2025|FierceBiotech|

Australian life sciences venture capital firm Brandon Capital has closed its largest fund yet, raising A$439 million (about $290 million) for the sixth Brandon BioCatalyst Fund. The heaps of cash will go toward fast-growing companies

Novartis is serving up $60 million…

July 24th, 2025|FierceBiotech|

Novartis is serving up $60 million to partner with Matchpoint Therapeutics in hopes of getting an oral covalent inhibitor over the line for inflammatory diseases that have been historically difficult to treat.

After ditching a plan to split…

July 24th, 2025|FierceBiotech|

After ditching a plan to split into two distinct companies, Belgian biotech Galapagos is trimming its pipeline and consolidating cell therapies to prep the business unit for a potential sale.

Adicet Bio is handing out pink…

July 24th, 2025|FierceBiotech|

Adicet Bio is handing out pink slips to 30% of its staffers in tandem with a pipeline restructure that includes discontinuing a clinical-stage allogeneic cell therapy. 

Rocket Pharmaceuticals is laying…

July 24th, 2025|FierceBiotech|

Rocket Pharmaceuticals is laying off 30% of its staff and focusing on its cardiovascular disease programs, causing delays to assets including a gene therapy that was on track to win approval next year.